EMA Committee Recommends Approval for NEZGLYAL® (leriglitazone) to Treat Rare Neurodegenerative Disease cALD

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending marketing authorization under exceptional circumstances for NEZGLYAL® (leriglitazone). This treatment is intended for males aged 2 to 12 years with Cerebral Adrenoleukodystrophy (cALD), a rare genetic neurodegenerative disorder, who have non-gadolinium enhancing lesions in brain MRI and a Neurological Functional Score of 0 or 1. European Commission approval is anticipated by the end of September 2026.

Context

Cerebral Adrenoleukodystrophy (cALD) is a genetic disorder that primarily affects males and leads to progressive neurological decline. Current treatment options are scarce, making the development of new therapies crucial. The EMA's Committee for Medicinal Products for Human Use (CHMP) plays a key role in evaluating new medications in Europe, and their positive opinion is a critical step toward market availability.

Why it matters

The recommendation for NEZGLYAL® represents a significant advancement in the treatment options for children suffering from cALD, a rare and severe neurodegenerative disease. This decision could improve the quality of life for affected patients and their families. The approval under exceptional circumstances highlights the urgent need for effective therapies in rare diseases where treatment options are limited.

Implications

If approved, NEZGLYAL® could become the first targeted treatment for cALD, potentially benefiting young patients diagnosed with this condition. The approval may also encourage further research and investment in therapies for rare diseases. Families affected by cALD may experience improved outcomes, while healthcare systems may need to adapt to incorporate this new treatment into care plans.

What to watch

The European Commission is expected to make a final decision on the marketing authorization for NEZGLYAL® by the end of September 2026. Stakeholders will be monitoring the approval process closely, as it may set a precedent for other rare disease treatments. Additionally, the response from the medical community and patient advocacy groups will be important in shaping future developments.